Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03798366 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis
A Phase 2 study, sponsored by Lakefront Biotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT03798366: Completed Phase 2 study, sponsored by Lakefront Biotherapeutics.
NCT03798366 is a Phase 2 study that has completed, run by Lakefront Biotherapeutics. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03798366, a Phase 2 study, has completed, sponsored by Lakefront Biotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The main purpose of the study is to see if GLPG1690 helps (together with the standard of care treatment) in the treatment of the skin and other areas affected by systemic sclerosis. Another aim is to find out how safe/well tolerated GLPG1690 will be and whether there are any side effects. The study will also look at other things, including whether the study drug affects disease progression and also if it changes any aspect of the quality of life.
Interventions
- DRUG Placebo
- DRUG GLPG1690
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2019-01-14 |
| Est. Completion | 2020-06-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03798366
The ClinicalTrials.gov registry entry for NCT03798366 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lakefront Biotherapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03798366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03798366 about?
NCT03798366 is a clinical study titled "A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis". The main purpose of the study is to see if GLPG1690 helps (together with the standard of care treatment) in the treatment of the skin and other areas affected by systemic sclerosis. Another aim is to find out how safe/well tolerated GLPG1690 will be and whether there are any side effects. The study...
What is the current status of trial NCT03798366?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2019-01-14. Estimated completion is 2020-06-22.
What interventions are being tested in trial NCT03798366?
The interventions under investigation include: Placebo (DRUG), GLPG1690 (DRUG).
Who is sponsoring clinical trial NCT03798366?
This trial is sponsored by Lakefront Biotherapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.